Streetbeat News

Earnings

PHUN

Phunware reported a significant Q4 EPS loss of $(17.62), vastly missing the $(2.00) estimate, while sales of $4.80M exceeded the $2.10M estimate. This represents a 17520% increase in losses and a slight 0.57% increase in sales year-over-year.

Portfolio Pulse from Happy Mohamed

March 12, 2024 | 8:31 pm

HRTX

Heron Therapeutics has reaffirmed its financial guidance for FY24, projecting net product revenues between $138M-$158M, adjusted operating expenses between $108M-$116M, and adjusted EBITDA ranging from a loss of $22M to a gain of $3M, excluding stock-based compensation and depreciation and amortization.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 8:30 pm

ALGS

Aligos Therapeutics (NASDAQ:ALGS) reported Q4 earnings, beating estimates with an EPS of $-0.22 against an expected $-0.27. However, revenue decreased by $1.53 million from the previous year. The company had previously seen a 1.0% stock price increase following last quarter's earnings beat.

Portfolio Pulse from Benzinga Insights

March 12, 2024 | 8:30 pm

GHLD

Guild Holdings (NYSE:GHLD) reported Q4 earnings with a 43.0% beat on estimated EPS, reporting $0.2 versus an estimate of $0.14. However, revenue was down $77.07 million from the same period last year. In the previous quarter, GHLD beat the EPS estimate which led to a 4.0% increase in share price the next day.

Portfolio Pulse from Benzinga Insights

March 12, 2024 | 8:30 pm

CLPT

ClearPoint Neuro (NASDAQ:CLPT) reported Q4 earnings with an EPS of $-0.19, beating estimates by 5.0% against an expected $-0.2. Revenue increased by $1.64 million year-over-year. Despite beating EPS estimates last quarter, CLPT's share price dropped by 18.0% the following day. The company has had mixed earnings performance over the past year, with fluctuations in both EPS and revenue.

Portfolio Pulse from Benzinga Insights

March 12, 2024 | 8:30 pm

ADTH

AdTheorent Holding (NASDAQ:ADTH) reported Q4 earnings with an EPS of $0.01, missing estimates by -86.0% against an expected $0.07. Revenue increased by $7.88 million from the previous year. The company's past earnings performance shows a pattern of missed EPS estimates leading to share price drops.

Portfolio Pulse from Benzinga Insights

March 12, 2024 | 8:30 pm

CLSD

Clearside Biomedical (NASDAQ:CLSD) reported Q4 earnings with an EPS of $-0.08, beating estimates by 11.0% and showing a revenue increase of $6.01 million from the previous year. Despite beating this quarter's earnings estimate, past performance shows mixed results with a miss in Q3 2023 followed by a 2.0% share price drop.

Portfolio Pulse from Benzinga Insights

March 12, 2024 | 8:30 pm

WEST

Westrock Coffee (NASDAQ:WEST) reported a Q4 EPS loss of $(0.23), marking a 47.73% improvement from the $(0.44) per share loss reported in the same quarter last year.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 8:29 pm

NARI

Inari Medical, Inc. (NASDAQ: NARI) announced positive two-year interim results from the CLOUT registry for its ClotTriever system, presented at the American Venous Forum. The results show excellent safety, effectiveness, and long-term outcomes in treating deep vein thrombosis (DVT), with significantly lower post-thrombotic syndrome (PTS) rates compared to historical studies. Inari's commitment to high-level research, including the DEFIANCE trial, aims to establish ClotTriever and FlowTriever systems as the standard of care for DVT and pulmonary embolism patients.

Portfolio Pulse from Happy Mohamed

March 12, 2024 | 8:29 pm

RXT

Rackspace Technology's shares dropped following its Q4 financial results announcement and Q1 guidance, which were below expectations. The company also announced refinancing transactions.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 8:29 pm